Role of Basic Fibroblast Growth Factor in Cancer: Biological Activity, Targeted Therapies, and Prognostic Value
Cells · 24.03.2023 · 12 (7) · 1002
DOI: 10.3390/cells12071002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 24.03.2023. Verfasst von Alessio Ardizzone und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno d'Alcontres, 98166 Mess…. Hauptthemen laut MEDLINE: Fibroblast Growth Factor 2, Neoplasms. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 222 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancer is the leading cause of death worldwide; thus, it is necessary to find successful strategies. Several growth factors, such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF, FGF2), and transforming growth factor beta (TGF-β), are involved in the main processes that fuel tumor growth, i.e., cell proliferation, angiogenesis, and metastasis, by activating important signaling pathways, including PLC-γ/PI3/Ca2+ signaling, leading to PKC activation. Here, we focused on bFGF, which, when secreted by tumor cells, mediates several signal transductions and plays an influential role in tumor cells and in the development of chemoresistance. The biological mechanism of bFGF is shown by its interaction with its four receptor subtypes: fibroblast growth factor receptor (FGFR) 1, FGFR2, FGFR3, and FGFR4. The bFGF–FGFR interaction stimulates tumor cell proliferation and invasion, resulting in an upregulation of pro-inflammatory and anti-apoptotic tumor cell proteins. Considering the involvement of the bFGF/FGFR axis in oncogenesis, preclinical and clinical studies have been conducted to develop new therapeutic strategies, alone and/or in combination, aimed at intervening on the bFGF/FGFR axis. Therefore, this review aimed to comprehensively examine the biological mechanisms underlying bFGF in the tumor microenvironment, the different anticancer therapies currently available that target the FGFRs, and the prognostic value of bFGF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno d'Alcontres, 98166 Messina, Italy.
- IOM Ricerca Srl, Via Penninazzo 11, 95029 Viagrande, Italy.
- Istituto Oncologico del Mediterraneo, Via Penninazzo 7, 95029 Viagrande, Italy.
ORCID-Profile: Alessio Ardizzone, Raffaella Giuffrida, Cristina Colarossi, Salvatore Cuzzocrea, Emanuela Esposito
Zitieren
APA
Ardizzone, A., Bova, V., Casili, G., Repici, A., Lanza, M., Giuffrida, R., Colarossi, C., Mare, M., Cuzzocrea, S., Esposito, E., & Paterniti, I. (2023). Role of Basic Fibroblast Growth Factor in Cancer: Biological Activity, Targeted Therapies, and Prognostic Value. Cells, 12(7), 1002. https://doi.org/10.3390/cells12071002
Vancouver
Ardizzone A, Bova V, Casili G, Repici A, Lanza M, Giuffrida R, et al. Role of Basic Fibroblast Growth Factor in Cancer: Biological Activity, Targeted Therapies, and Prognostic Value. Cells. 2023;12(7):1002. doi:10.3390/cells12071002
BibTeX
@article{Ardizzone2023,
author = {Ardizzone, Alessio and Bova, Valentina and Casili, Giovanna and Repici, Alberto and Lanza, Marika and Giuffrida, Raffaella and Colarossi, Cristina and Mare, Marzia and Cuzzocrea, Salvatore and Esposito, Emanuela and Paterniti, Irene},
title = {Role of Basic Fibroblast Growth Factor in Cancer: Biological Activity, Targeted Therapies, and Prognostic Value},
journal = {Cells},
year = {2023},
volume = {12},
number = {7},
pages = {1002},
doi = {10.3390/cells12071002}
}
EUVIMED